Brimonidine prevents axonal and somatic degeneration of retinal ganglion cell neurons
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background: Brimonidine is a common drug for lowering ocular pressure and may directly protect retinal ganglion cells in glaucoma. The disease involves early loss of retinal ganglion cell transport to brain targets followed by axonal and somatic degeneration. We examined whether brimonidine preserves ganglion cell axonal transport and abates degeneration in rats with elevated ocular pressure induced by laser cauterization of the episcleral veins. Results: Ocular pressure was elevated unilaterally by 90% for a period of 8 weeks post- cauterization. During this time, brimonidine (1mg/kg/day) or vehicle (phosphate-buffered saline) was delivered systemically and continuously via subcutaneous pump. Animals received bilateral intravitreal injections of fluorescent cholera toxin subunit β (CTB) two days before sacrifice to assess anterograde transport. In retinas from the vehicle group, elevated pressure induced a 44% decrease in the fraction of ganglion cells with intact uptake of CTB and a 14-42% reduction in the number of immuno-labelled ganglion cell bodies, with the worst loss occurring nasally. Elevated pressure also caused a 33% loss of ganglion cell axons in vehicle optic nerves and a 70% decrease in CTB transport to the superior colliculus. Each of these components of ganglion cell degeneration was either prevented or significantly reduced in the brimonidine treatment group. Conclusions: Continuous and systemic treatment with brimonidine by subcutaneous injection significantly improved retinal ganglion cell survival with exposure to elevated ocular pressure. This effect was most striking in the nasal region of the retina. Brimonidine treatment also preserved ganglion cell axon morphology, sampling density and total number in the optic nerve with elevated pressure. Consistent with improved outcome in the optic projection, brimonidine also significantly reduced the deficits in axonal transport to the superior colliculus associated with elevated ocular pressure. As transport deficits to and from retinal ganglion cell projection targets in the brain are relevant to the progression of glaucoma, the ability of brimonidine to preserve optic nerve axons and active transport suggests its neuroprotective effects are relevant not only at the cell body, but throughout the entire optic projection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distal axonopathy with structural persistence in glaucomatous neurodegeneration
Crish, S. D., Sappington, R. M., Inman, D. M., Horner, P. J., & Calkins, D. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913141107 · Cited by 350
Self-citationSchlamp, C. L., Li, Y., Dietz, J. A., Janssen, K. T., & Nickells, R. W. (2006) · BMC Neuroscience · doi:10.1186/1471-2202-7-66 · Cited by 303
CRMP-2 Is Involved in Kinesin-1-Dependent Transport of the Sra-1/WAVE1 Complex and Axon Formation
Kawano, Y., Yoshimura, T., Tsuboi, D., Kawabata, S., Kaneko-Kawano, T., Shirataki, H., Takenawa, T., & Kaibuchi, K. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.22.9920-9935.2005 · Cited by 241 · cited 1×
“GSK3 also phosphorylates collapsin response mediator protein-2, which promotes microtubule assembly and links tubulin heterodimers to kinesin-1 to regulate protein transport to distal regions of axons [ 56-58 ].”
Background
Cited by
Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma
Zhang, K., Zhang, L., & Weinreb, R. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3745 · Cited by 316
Critical pathogenic events underlying progression of neurodegeneration in glaucoma
Calkins, D. J. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2012.07.001 · Cited by 309
Self-citationAge-related changes in the visual pathways: blame it on the axon
Calkins, D. J. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-12784 · Cited by 96
“Central targets in the brain and RGC bodies in the retina persist for a period following axonopathy that represents a window of therapeutic opportunity.(57) Similarly, the broad survey presented here indicates a special vulnerability of the RGC axon to age-related decline, with a consistent loss of approximately 40% o…”
BackgroundSelf-citationProximal inhibition of p38 MAPK stress signaling prevents distal axonopathy
Dapper, J. D., Crish, S. D., Pang, I.-H., & Calkins, D. J. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.07.001 · Cited by 76
Self-citationLambert, W. S., Carlson, B. J., Formichella, C. R., Sappington, R. M., Ahlem, C., & Calkins, D. J. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00045 · Cited by 31
“Experimental interventions that prevent transport deficits are efficacious at stopping subsequent degeneration of axons and cell bodies (Lambert et al., 2011; Dapper et al., 2013).”
BackgroundResultInfluentialSelf-citation
Metadata
- Authors
- Lambert, W. S., Ruiz, L., Crish, S. D., Wheeler, L. A., & Calkins, D. J.
- Venue
- Molecular Neurodegeneration
- Published
- 2011-01-13
- Volume
- 6
- Issue
- 1
- Pages
- 4-4
- ISSN
- 1750-1326 (ISSN-L)
- OpenAlex
- W2062537640
- Cited by
- 108
- References
- 3
- FWCI
- 8.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Brimonidine prevents axonal and somatic degeneration of retinal ganglion cell neurons. https://app.cochat.ai/papers/10.1186/1750-1326-6-4
- The paper
- Lambert, W. S., Ruiz, L., Crish, S. D., Wheeler, L. A., & Calkins, D. J. (2011). Brimonidine prevents axonal and somatic degeneration of retinal ganglion cell neurons. Molecular Neurodegeneration. https://doi.org/10.1186/1750-1326-6-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.